MEDICINE & HEALTH

Trial

Entasis Therapeutics Announces Positive Topline Results for Sulbactam-durlobactam (SUL-DUR) From Phase 3 ATTACK Trial

Entasis Therapeutics Holdings Inc. (Nasdaq:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced topline results from its ATTACK trial―a global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii.
Neuroscience

World Experts Meet in Colombia for International Neuroscience Congress

The event will feature the participation of John O'Keefe, British-American neuroscientist and psychologist who, in 2014, together with Edvard Moser and May Britt received the Nobel Prize in Medicine. The wonders of the brain and neuroscience at UNAB, Universidad Autónoma de Bucaramanga, Colombia.

Recommended Stories